CGEN - コンピュジェン (Compugen Ltd.) コンピュジェン

 CGENのチャート


 CGENの企業情報

symbol CGEN
会社名 Compugen Ltd (コンピュジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンピュジェン(Compugen Ltd.)は治療薬の発見会社で、免疫学と腫瘍学分野での満たされていない重要なニーズに対応する治療用タンパク質及びモノクローナル抗体を中心とする。同社は主に発見された製品候補のさらなる開発・商業化及び各種形態の研究・発見契約を含む提携を行う。同社のプログラムパイプラインは検証から前臨床試験に至るまで様々な段階における30種類以上の治療薬候補で構成される。パイプラインプログラムの下で、新たに発見された分子はシリコン内での予測と選択の直後での実験的評価を開始する時にプログラムに入る。パイプラインプログラムは追加の18ヶ月間以下の特定分子向けの様々な前臨床活動が続く動物疾患モデルや重複実験を含む生体内及び生体内の実験的検証で構成される。   コンピュジェンはイスラエルの製薬会社。モノクロ―ナル抗体および腫瘍学および免疫学の分野の治療用タンパク質に焦点を当て薬剤の開発を行う。同社は、伝統的な実験に基づく薬物候補の発見とは異なり、コンピュ―タによって独自の科学的理解および予測プラットフォ―ム、アルゴリズム、機械学習システムを利用し、予測し製品候補の開発を行う。本社はテレアビブ。   
本社所在地 Azrieli Center 26 Harokmim Street Building D Holon 5885849 ISR
代表者氏名 Paul Jai Sekhri ポール・ジャイ・セクフリ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-765-8585
設立年月日 34001
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 101人
url www.cgen.com
nasdaq_url https://www.nasdaq.com/symbol/cgen
adr_tso
EBITDA EBITDA(百万ドル) -29.58400
終値(lastsale) 3.36
時価総額(marketcap) 192182017.44
時価総額 時価総額(百万ドル) 194.16020
売上高 売上高(百万ドル) 10.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151.70420
当期純利益 当期純利益(百万ドル) -29.27000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Compugen Ltd. (USA) revenues increased from $0K to $10M. Net loss decreased 44% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.35 to -$0.19.

 CGENのテクニカル分析


 CGENのニュース

   Compugen (NASDAQ:CGEN) Stock Rating Lowered by BidaskClub  2020/10/23 01:26:45 Stock Observer
Compugen (NASDAQ:CGEN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports. Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, […]
   Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.09 Per Share  2020/10/20 16:00:42 The Olympia Report
Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Compugen’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Compugen reported earnings per share of ($0.10) in the same quarter last year, […]
   Analysts Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $19.56  2020/10/19 18:56:49 Transcript Daily
Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $19.56. […]
   Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors  2020/09/09 05:35:29 Smarter Analyst
Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers … The post Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors appeared first on Smarter Analyst .
   We spoke to 3 financial experts, who broke down why you should buy these 13 ETFs to maximize stock-market returns right now  2020/06/11 12:26:15 Business Insider
With the stock market climbing off multiyear lows, investors are seeking opportunities in a market that's confounded even the top Wall Street strategists. One way to gain diverse exposure to a basket of companies, rather than individual stocks, is to purchase exchange-traded funds. Business Insider interviewed three ETF experts to get their top picks for funds designed to play themes ranging from international equities, to healthcare, to video games and esports. Click here to sign up for our weekly newsletter Investing Insider . Click here for more BI Prime stories . US equity markets have recovered a large chunk of losses absorbed amid the coronavirus pandemic. That's largely due to the Federal Reserve's lowering of interest rates to near zero, as well as its continued commitment to mammoth quantitative easing efforts. Surprisingly positive economic data in recent days has also been a source of the optimism driving markets. As the rebound has played out, some experts have questioned whether the market is overvalued and have argued that the current risk-reward ratio is too high. "For me personally, it's an uncomfortable bet to continue to bet on a huge recovery," Allianz Chief Economic Advisor Mohamed El-Erian said on CNBC Monday morning, for instance.
   Compugen (NASDAQ:CGEN) Stock Rating Lowered by BidaskClub  2020/10/23 01:26:45 Stock Observer
Compugen (NASDAQ:CGEN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports. Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, […]
   Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.09 Per Share  2020/10/20 16:00:42 The Olympia Report
Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Compugen’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Compugen reported earnings per share of ($0.10) in the same quarter last year, […]
   Analysts Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $19.56  2020/10/19 18:56:49 Transcript Daily
Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $19.56. […]
   Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors  2020/09/09 05:35:29 Smarter Analyst
Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers … The post Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors appeared first on Smarter Analyst .
   We spoke to 3 financial experts, who broke down why you should buy these 13 ETFs to maximize stock-market returns right now  2020/06/11 12:26:15 Business Insider
With the stock market climbing off multiyear lows, investors are seeking opportunities in a market that's confounded even the top Wall Street strategists. One way to gain diverse exposure to a basket of companies, rather than individual stocks, is to purchase exchange-traded funds. Business Insider interviewed three ETF experts to get their top picks for funds designed to play themes ranging from international equities, to healthcare, to video games and esports. Click here to sign up for our weekly newsletter Investing Insider . Click here for more BI Prime stories . US equity markets have recovered a large chunk of losses absorbed amid the coronavirus pandemic. That's largely due to the Federal Reserve's lowering of interest rates to near zero, as well as its continued commitment to mammoth quantitative easing efforts. Surprisingly positive economic data in recent days has also been a source of the optimism driving markets. As the rebound has played out, some experts have questioned whether the market is overvalued and have argued that the current risk-reward ratio is too high. "For me personally, it's an uncomfortable bet to continue to bet on a huge recovery," Allianz Chief Economic Advisor Mohamed El-Erian said on CNBC Monday morning, for instance.
   Compugen (NASDAQ:CGEN) Stock Rating Lowered by BidaskClub  2020/10/23 01:26:45 Stock Observer
Compugen (NASDAQ:CGEN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports. Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, […]
   Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.09 Per Share  2020/10/20 16:00:42 The Olympia Report
Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Compugen’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Compugen reported earnings per share of ($0.10) in the same quarter last year, […]
   Analysts Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $19.56  2020/10/19 18:56:49 Transcript Daily
Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $19.56. […]
   Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors  2020/09/09 05:35:29 Smarter Analyst
Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers … The post Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors appeared first on Smarter Analyst .
   We spoke to 3 financial experts, who broke down why you should buy these 13 ETFs to maximize stock-market returns right now  2020/06/11 12:26:15 Business Insider
With the stock market climbing off multiyear lows, investors are seeking opportunities in a market that's confounded even the top Wall Street strategists. One way to gain diverse exposure to a basket of companies, rather than individual stocks, is to purchase exchange-traded funds. Business Insider interviewed three ETF experts to get their top picks for funds designed to play themes ranging from international equities, to healthcare, to video games and esports. Click here to sign up for our weekly newsletter Investing Insider . Click here for more BI Prime stories . US equity markets have recovered a large chunk of losses absorbed amid the coronavirus pandemic. That's largely due to the Federal Reserve's lowering of interest rates to near zero, as well as its continued commitment to mammoth quantitative easing efforts. Surprisingly positive economic data in recent days has also been a source of the optimism driving markets. As the rebound has played out, some experts have questioned whether the market is overvalued and have argued that the current risk-reward ratio is too high. "For me personally, it's an uncomfortable bet to continue to bet on a huge recovery," Allianz Chief Economic Advisor Mohamed El-Erian said on CNBC Monday morning, for instance.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンピュジェン CGEN Compugen Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)